Quick Answer
CHINA PHARMA HOLDINGS, INC. reported R&D Expense of $283.9 thousand for fiscal year 2024.
CHINA PHARMA HOLDINGS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $283.9K | +18.3% |
| 2023 | $240.1K | +29.2% |
| 2022 | $185.9K | -41.7% |
| 2021 | $319.0K | -15.6% |
| 2020 | $378.0K | +64.6% |
| 2019 | $229.6K | +33.2% |
| 2018 | $172.4K | +90.5% |
| 2017 | $90.5K | -75.3% |
| 2016 | $366.0K | -62.0% |
| 2015 | $961.9K | -65.6% |
| 2014 | $2.80M | +66.3% |
| 2013 | $1.68M | +283.7% |
| 2012 | $438.7K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $40.3K | -54.0% | +92.4% |
| June 30, 2025 | $21.0K | -87.3% | -29.2% |
| March 31, 2025 | $29.6K | -5.9% | -66.2% |
| September 30, 2024 | $87.6K | +91.4% | -46.7% |
| June 30, 2024 | $164.3K | +592.0% | +422.5% |
| March 31, 2024 | $31.5K | +36.7% | -31.3% |
| September 30, 2023 | $45.8K | -48.4% | +92.8% |
| June 30, 2023 | $23.7K | +57.7% | +3.2% |
- CHINA PHARMA HOLDINGS, INC. showed an increase of +18.3% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2024 period, CHINA PHARMA HOLDINGS, INC.’s r&d expense has declined by 35.3% (from $438.7 thousand to $283.9 thousand).
- The most recent figure is from CHINA PHARMA HOLDINGS, INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: